

MAY RESURBATION 13 MAR 2006



PATENT Attorney Docket No. 186208/RFT Client Matter No. 455569-14

UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Frederic Colland, et al.

Int'l Application No.: PCT/EP03/07399

Int'l Filing Date: July 8, 2003

U.S. Application No.: 10/520,712

For:

TCF/β Regulated Genes for

Treatment of Cancer

Examiner:

TBA

Group Art Unit:

TBA

Confirmation No. 2640

CERTIFICATE OF MAILING

I hereby certify that this correspondence and its listed enclosures is being deposited with sufficient postage with the United States Postal Service as First Class Mail addressed to Commissioner for Patents, P.O. Box 1450, Alexandria,

Virginia 22313-1450 on March 10, 2006.

Signed

Victoria Linne Poulsen

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, Virginia 22313-1450

Further to Applicant's Information Disclosure Statement filed March 1, 2006, and in satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trademark Office to the references cited on the accompanying form PTO/SB/8A. In accordance with 1287 Off. Gaz. Pat. Office 163, 10/19/2004, no copies of U.S. patents and U.S. published applications are enclosed. Copies of foreign patents and non-patent literature[, unless indicated otherwise below,] are enclosed.

Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application. Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

Although Applicant does not believe any additional fees are due, the Commissioner is hereby authorized to charge any such fees, including extension fees, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. 186208/US/2/RFT [455569-14]).

Respectfully submitted, DORSEY & WHITNEY LLP

Richard F. Trecartin, Reg. No. 31,801

555 California Street, Suite 1000 San Francisco, California 94104-1513

Telephone: (415) 781-1989 Facsimile: (415) 398-3249 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			VPTO	Complete if Known		
(Modified) INFORMATION DISCLOSURE				Application Number	10/520/712	
				Filing Date	July 8, 2003	
S	STATEMENT BY APPLICANT			First Named Inventor	Colland, et al.	
				Art Unit	To be assigned	
(use as many sheets as necessary)				Examiner Name	To be assigned	
Sheet	1	of	1	Attorney Docket Number	Docket 186208 US 455569-14	

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	A1						
	A2						
_	A3	US-					
	A4	US-					
	A5	US-					
	A6	US-					
	A7	US-					
	A8	US-					
	A9	US-					
	A10	US-					

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
	B1						

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T⁵	
	C1	Hsu et al., "Characterization of Two LGR Genes Homologous to Gonadotropin and Thyrotropin Receptors with Extracellular Luecine-Rich Repeats and a G Protein-Coupled, Seven Transmembrane Region" <i>Mol. Endocrinology,</i> (1998) Vol. 12, No. 12, pps. 1830-1845		

Examiner Signature	,	Date Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English Language Translation is attached.